FY2027 Earnings Forecast for Alector, Inc. (NASDAQ:ALEC) Issued By HC Wainwright

Alector, Inc. (NASDAQ:ALEC – Get Rating) – Analysts at HC Wainwright issued their FY2027 earnings estimates for Alector in a report released on Wednesday, March 1st. HC Wainwright analyst A. Fein expects that the company will earn ($0.64) per share for the year. HC Wainwright currently has a “Buy” rating and a $41.00 target price on the stock. The consensus estimate for Alector’s current full-year earnings is ($1.39) per share.

A number of other research firms have also issued reports on ALEC. TheStreet lowered shares of Alector from a “c-” rating to a “d” rating in a research report on Friday, November 11th. BTIG Research cut their price objective on shares of Alector from $54.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday. Citigroup cut their price objective on shares of Alector from $17.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday. Bank of America lowered shares of Alector from a “buy” rating to a “neutral” rating and cut their price objective for the company from $24.00 to $12.00 in a research report on Friday, January 6th. Finally, Morgan Stanley cut their price objective on shares of Alector from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Tuesday, January 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Alector presently has a consensus rating of “Hold” and a consensus price target of $16.11.

Alector Price Performance

NASDAQ ALEC opened at $8.24 on Thursday. The company has a 50 day simple moving average of $8.99 and a 200-day simple moving average of $9.18. The firm has a market capitalization of $681.45 million, a price-to-earnings ratio of -5.12 and a beta of 0.83. Alector has a 52-week low of $6.84 and a 52-week high of $15.72.

Institutional Investors Weigh In On Alector

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP acquired a new stake in shares of Alector in the first quarter worth $25,000. Great West Life Assurance Co. Can acquired a new stake in shares of Alector in the third quarter worth $27,000. Lazard Asset Management LLC lifted its position in Alector by 99.2% in the second quarter. Lazard Asset Management LLC now owns 6,231 shares of the company’s stock worth $63,000 after purchasing an additional 3,103 shares during the period. Point72 Hong Kong Ltd bought a new position in Alector in the third quarter worth $65,000. Finally, Alpine Global Management LLC bought a new position in Alector in the fourth quarter worth $93,000. Institutional investors and hedge funds own 64.96% of the company’s stock.

Alector Company Profile

(Get Rating)

Alector, Inc operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.